Stephen L. Atkin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5213815/publications.pdf

Version: 2024-02-01

342 papers 12,345 citations

56 h-index 91 g-index

350 all docs 350 does citations

350 times ranked

14453 citing authors

#	Article	IF	CITATIONS
1	Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and metaâ€analysis of randomized controlled trials. Clinical Endocrinology, 2022, 96, 758-780.	2.4	2
2	Hypoglycemia Impairs the Heat Shock Protein Response: A Risk for Heat Shock in Cattle?. Frontiers in Veterinary Science, 2022, 9, 822310.	2.2	0
3	Diagnostic and Prognostic Protein Biomarkers of \hat{l}^2 -Cell Function in Type 2 Diabetes and Their Modulation with Glucose Normalization. Metabolites, 2022, 12, 196.	2.9	5
4	Postradioiodine Graves' management: The PRAGMA study. Clinical Endocrinology, 2022, 97, 664-675.	2.4	3
5	Severe iatrogenic hypoglycaemia modulates the fibroblast growth factor protein response. Diabetes, Obesity and Metabolism, 2022, 24, 1483-1497.	4.4	1
6	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular Metabolism, 2021, 50, 101049.	6.5	42
7	The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects. International Journal of Infectious Diseases, 2021, 102, 285-288.	3.3	48
8	Diagnosing type 2 diabetes using Hemoglobin A1c: a systematic review and meta-analysis of the diagnostic cutpoint based on microvascular complications. Acta Diabetologica, 2021, 58, 279-300.	2.5	10
9	Letter to the Editor: Do biomarkers of COVID-19 severity simply reflect a stress response in type 2 diabetes: Biomarker response to hypoglycemia. Metabolism: Clinical and Experimental, 2021, 114, 154417.	3.4	2
10	Hypoglycaemia in type <scp>2</scp> diabetes exacerbates amyloidâ€related proteins associated with dementia. Diabetes, Obesity and Metabolism, 2021, 23, 338-349.	4.4	17
11	GLP-1 mimetics and cognition. Life Sciences, 2021, 264, 118645.	4.3	32
12	Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome. Journal of Translational Medicine, 2021, 19, 63.	4.4	2
13	Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?. Frontiers in Endocrinology, 2021, 12, 638621.	3.5	11
14	Association of Complement-Related Proteins in Subjects With and Without Second Trimester Gestational Diabetes. Frontiers in Endocrinology, 2021, 12, 641361.	3.5	6
15	The relationship of soluble neuropilin-1 to severe COVID-19 risk factors in polycystic ovary syndrome. Metabolism Open, 2021, 9, 100079.	2.9	8
16	Glucose excursions in type 2 diabetes modulate amyloid-related proteins associated with dementia. Journal of Translational Medicine, 2021, 19, 131.	4.4	6
17	Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19. Scientific Reports, 2021, 11, 6428.	3.3	13
18	apoA2 correlates to gestational age with decreased apolipoproteins A2, C1, C3 and E in gestational diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e001925.	2.8	7

#	Article	IF	CITATIONS
19	Mapping of type 2 diabetes proteins to COVID-19 biomarkers: A proteomic analysis. Metabolism Open, 2021, 9, 100074.	2.9	3
20	Platelet Protein-Related Abnormalities in Response to Acute Hypoglycemia in Type 2 Diabetes. Frontiers in Endocrinology, 2021, 12, 651009.	3. 5	7
21	Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome. Scientific Reports, 2021, 11, 5320.	3.3	16
22	Plasma heat shock protein response to euglycemia in type 2 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e002057.	2.8	12
23	Regulation of circulating CTRP-2/CTRP-9 and GDF-8/GDF-15 by intralipids and insulin in healthy control and polycystic ovary syndrome women following chronic exercise training. Lipids in Health and Disease, 2021, 20, 34.	3.0	5
24	The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19. International Journal of Infectious Diseases, 2021, 105, 656-661.	3.3	52
25	Amyloid-related protein changes associated with dementia differ according to severity of hypoglycemia. BMJ Open Diabetes Research and Care, 2021, 9, e002211.	2.8	4
26	Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity. Frontiers in Endocrinology, 2021, 12, 658304.	3.5	3
27	Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection?. Frontiers in Endocrinology, 2021, 12, 665134.	3 . 5	2
28	Vitamin D association with coagulation factors in polycystic ovary syndrome is dependent upon body mass index. Journal of Translational Medicine, 2021, 19, 239.	4.4	5
29	Vitamin D deficiency effects on cardiovascular parameters in women with polycystic ovary syndrome: A retrospective, cross-sectional study. Journal of Steroid Biochemistry and Molecular Biology, 2021, 211, 105892.	2.5	4
30	Impact of severe hypoglycemia on the heat shock and related protein response. Scientific Reports, 2021, 11, 17057.	3.3	9
31	Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus. BioMed Research International, 2021, 2021, 1-7.	1.9	5
32	The role of incretins and incretin-based drugs in autoimmune diseases. International Immunopharmacology, 2021, 98, 107845.	3.8	9
33	Association of microRNAs With Embryo Development and Fertilization in Women Undergoing Subfertility Treatments: A Pilot Study. Frontiers in Reproductive Health, 2021, 3, .	1.9	4
34	Impact of Incretin-Based Therapies on Adipokines and Adiponectin. Journal of Diabetes Research, 2021, 2021, 1-9.	2.3	7
35	Angiopoietin-1: an early biomarker of diabetic nephropathy?. Journal of Translational Medicine, 2021, 19, 427.	4.4	6
36	Vitamin D association with the renin angiotensin system in polycystic ovary syndrome. Journal of Steroid Biochemistry and Molecular Biology, 2021, 214, 105965.	2.5	4

#	Article	IF	Citations
37	GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-11.	1.9	17
38	Hypoglycemia-induced changes in complement pathways in type 2 diabetes. Atherosclerosis Plus, 2021, , .	0.7	2
39	Heat Shock-Related Protein Responses and Inflammatory Protein Changes Are Associated with Mild Prolonged Hypoglycemia. Cells, 2021, 10, 3109.	4.1	4
40	Potential Biomarkers to Predict Acute Ischemic Stroke in Type 2 Diabetes. Frontiers in Molecular Biosciences, 2021, 8, 744459.	3.5	5
41	Investigation of the Effects of Difluorinated Curcumin on Glycemic Indices in Streptozotocin-Induced Diabetic Rats. Advances in Experimental Medicine and Biology, 2021, 1328, 131-141.	1.6	3
42	MicroRNAs as important regulators of the NLRP3 inflammasome. Progress in Biophysics and Molecular Biology, 2020, 150, 50-61.	2.9	46
43	Impaired heat shock protein 72 expression in women with polycystic ovary syndrome following a supervised exercise programme. Cell Stress and Chaperones, 2020, 25, 73-80.	2.9	2
44	Physiologically relevant screening of polyphenol-rich commercial preparations for bioactivity in vascular endothelial cells and application to healthy volunteers: A viable workflow and a cautionary tale. Biochemical Pharmacology, 2020, 173, 113754.	4.4	3
45	Association of vitamin D ₃ and its metabolites in patients with and without type 2 diabetes and their relationship to diabetes complications. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232092415.	2.5	18
46	COVID-19 and sickle cell disease in Bahrain. International Journal of Infectious Diseases, 2020, 101, 14-16.	3.3	26
47	Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection?. Metabolism Open, 2020, 7, 100052.	2.9	20
48	Qatari Genotype May Contribute to Complications in Type 2 Diabetes. Journal of Diabetes Research, 2020, 2020, 1-6.	2.3	1
49	miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review. Life Sciences, 2020, 259, 118174.	4.3	47
50	Increased MicroRNA Levels in Women With Polycystic Ovarian Syndrome but Without Insulin Resistance: A Pilot Prospective Study. Frontiers in Endocrinology, 2020, 11, 571357.	3.5	14
51	Vitamin D3 metabolite ratio as an indicator of vitamin D status and its association with diabetes complications. BMC Endocrine Disorders, 2020, 20, 161.	2.2	17
52	The metabolic footprint of compromised insulin sensitivity under fasting and hyperinsulinemic-euglycemic clamp conditions in an Arab population. Scientific Reports, 2020, 10, 17164.	3.3	5
53	Metabolic profiling of pre-gestational and gestational diabetes mellitus identifies novel predictors of pre-term delivery. Journal of Translational Medicine, 2020, 18, 366.	4.4	14
54	Pro-fibrotic M2 macrophage markers may increase the risk for COVID19 in type 2 diabetes with obesity. Metabolism: Clinical and Experimental, 2020, 112, 154374.	3.4	6

#	Article	IF	CITATIONS
55	Metabolic comparison of polycystic ovarian syndrome and control women in Middle Eastern and UK Caucasian populations. Scientific Reports, 2020, 10, 18895.	3.3	9
56	Association of vitamin D2 and D3 with type 2 diabetes complications. BMC Endocrine Disorders, 2020, 20, 65.	2.2	22
57	Association of endocrine active environmental compounds with body mass index and weight loss following bariatric surgery. Clinical Endocrinology, 2020, 93, 280-287.	2.4	8
58	Analysis of 52 C19 and C21 steroids by UPC2-MS/MS: Characterising the C11-oxy steroid metabolome in serum. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1152, 122243.	2.3	7
59	Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjects. Scientific Reports, 2020, 10, 4750.	3.3	69
60	Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	4.0	323
61	Long non-coding RNA expression in non-obese women with polycystic ovary syndrome and weight-matched controls. Reproductive BioMedicine Online, 2020, 41, 579-583.	2.4	2
62	Sporopollenin exine capsules (SpECs) derived from Lycopodium clavatum provide practical antioxidant properties by retarding rancidification of an ï‰-3 oil. Industrial Crops and Products, 2020, 154, 112714.	5.2	14
63	Renin-Angiotensin System Overactivation in Type 2 Diabetes: A Risk for SARS-CoV-2 Infection?. Diabetes Care, 2020, 43, e131-e133.	8.6	7
64	microRNA Expression in Women With and Without Polycystic Ovarian Syndrome Matched for Body Mass Index. Frontiers in Endocrinology, 2020, 11, 206.	3.5	21
65	The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: a clinical review. Lipids in Health and Disease, 2020, 19, 66.	3.0	36
66	Association of Differing Qatari Genotypes with Vitamin D Metabolites. International Journal of Endocrinology, 2020, 2020, 1-6.	1.5	4
67	COVID-19 biomarkers for severity mapped to polycystic ovary syndrome. Journal of Translational Medicine, 2020, 18, 490.	4.4	7
68	The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome. Endocrine Connections, 2020, 9, 563-569.	1.9	15
69	A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 328-334.	1.2	20
70	Perceptions, Knowledge, and Behaviors Related to COVID-19 Among Social Media Users: Cross-Sectional Study. Journal of Medical Internet Research, 2020, 22, e19913.	4.3	44
71	Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. Journal of Cellular Physiology, 2019, 234, 223-230.	4.1	97
72	Evidence of curcumin and curcumin analogue effects in skin diseases: A narrative review. Journal of Cellular Physiology, 2019, 234, 1165-1178.	4.1	113

#	Article	IF	CITATIONS
73	The protective role of curcumin in myocardial ischemia–reperfusion injury. Journal of Cellular Physiology, 2019, 234, 214-222.	4.1	125
74	A review of the molecular mechanisms of hyperglycemiaâ€induced free radical generation leading to oxidative stress. Journal of Cellular Physiology, 2019, 234, 1300-1312.	4.1	156
75	The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome. Frontiers in Endocrinology, 2019, 10, 394.	3.5	12
76	Effects of newly introduced antidiabetic drugs on autophagy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2445-2449.	3.6	33
77	Creatine Kinase Is a Marker of Metabolic Syndrome in Qatari Women With and Without Polycystic Ovarian Syndrome. Frontiers in Endocrinology, 2019, 10, 659.	3.5	5
78	Alterations in long noncoding RNAs in women with and without polycystic ovarian syndrome. Clinical Endocrinology, 2019, 91, 793-797.	2.4	15
79	Expression of microRNA in follicular fluid in women with and without PCOS. Scientific Reports, 2019, 9, 16306.	3.3	50
80	The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects. Endocrine, 2019, 66, 220-225.	2.3	2
81	Serum measures of hexabromocyclododecane (HBCDD) and polybrominated diphenyl ethers (PBDEs) in reproductive-aged women in the United Kingdom. Environmental Research, 2019, 177, 108631.	7.5	33
82	A response to "In response to â€~Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways'― Journal of Cellular Physiology, 2019, 234, 9908-9909.	4.1	2
83	A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. Nutrients, 2019, 11, 188.	4.1	61
84	Expression and localization of transient receptor potential channels in the bovine uterus epithelium throughout the estrous cycle. Molecular Biology Reports, 2019, 46, 4077-4084.	2.3	1
85	Bariatric Surgery Modulates Urinary Levels of MicroRNAs Involved in the Regulation of Renal Function. Frontiers in Endocrinology, 2019, 10, 319.	3.5	8
86	The Effects of Soy Protein and Cocoa With or Without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study. Frontiers in Endocrinology, 2019, 10, 296.	3.5	22
87	A systematic review and meta-analysis of the effect of curcuminoids on adiponectin levels. Obesity Research and Clinical Practice, 2019, 13, 340-344.	1.8	12
88	Lipids and insulin regulate mitochondrial $\hat{\epsilon}$ derived peptide (MOTS $\hat{\epsilon}$) in PCOS and healthy subjects. Clinical Endocrinology, 2019, 91, 278-287.	2.4	29
89	The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. Frontiers in Endocrinology, 2019, 10, 189.	3.5	20
90	C1q/TNF-related protein-3 and glucose homeostasis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1923-1927.	3.6	9

#	Article	IF	Citations
91	Circulating Endothelial Microparticles Reduce in Concentration Following an Exercise Programme in Women With Polycystic Ovary Syndrome. Frontiers in Endocrinology, 2019, 10, 200.	3.5	13
92	The Effect of Soy Isoflavones on Steroid Metabolism. Frontiers in Endocrinology, 2019, 10, 229.	3.5	12
93	Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1679-1683.	3 . 6	11
94	Systematic Review and Meta-analysis on the Effect of Soy on Thyroid Function. Scientific Reports, 2019, 9, 3964.	3.3	32
95	Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clinical Endocrinology, 2019, 90, 805-813.	2.4	68
96	Winglessâ€type inducible signaling pathway proteinâ€1 (WISP1) adipokine and glucose homeostasis. Journal of Cellular Physiology, 2019, 234, 16966-16970.	4.1	9
97	Association of Vitamin D Metabolites With Embryo Development and Fertilization in Women With and Without PCOS Undergoing Subfertility Treatment. Frontiers in Endocrinology, 2019, 10, 13.	3.5	24
98	Metabolomics of Dynamic Changes in Insulin Resistance Before and After Exercise in PCOS. Frontiers in Endocrinology, 2019, 10, 116.	3.5	29
99	Use of stem cells as carriers of oncolytic viruses for cancer treatment. Journal of Cellular Physiology, 2019, 234, 14906-14913.	4.1	18
100	Natural compounds with DPPâ€4 inhibitory effects: Implications for the treatment of diabetes. Journal of Cellular Biochemistry, 2019, 120, 10909-10913.	2.6	14
101	Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881880567.	3.2	6
102	Antiâ€inflammatory effects of resolvins in diabetic nephropathy: Mechanistic pathways. Journal of Cellular Physiology, 2019, 234, 14873-14882.	4.1	28
103	Potential roles of microRNAs in redox state: An update. Journal of Cellular Biochemistry, 2019, 120, 1679-1684.	2.6	10
104	Protective effects of curcumin against ischemia-reperfusion injury in the liver. Pharmacological Research, 2019, 141, 53-62.	7.1	51
105	Molecular mechanisms by which aerobic exercise induces insulin sensitivity. Journal of Cellular Physiology, 2019, 234, 12385-12392.	4.1	51
106	The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls. Gynecological Endocrinology, 2019, 35, 142-145.	1.7	20
107	Interleukinâ€18 and diabetic nephropathy: A review. Journal of Cellular Physiology, 2019, 234, 5674-5682.	4.1	74
108	A review of the antiâ€inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. Journal of Cellular Physiology, 2019, 234, 8286-8294.	4.1	51

#	Article	IF	Citations
109	Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function. Journal of Cellular Physiology, 2019, 234, 8402-8410.	4.1	52
110	Sodium–glucose cotransporter inhibitors and oxidative stress: An update. Journal of Cellular Physiology, 2019, 234, 3231-3237.	4.1	99
111	A review of the molecular pathways mediating the improvement in diabetes mellitus following caloric restriction. Journal of Cellular Physiology, 2019, 234, 8436-8442.	4.1	9
112	High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art. Trends in Endocrinology and Metabolism, 2019, 30, 12-24.	7.1	49
113	Current evidence and future perspectives for curcumin and its analogues as promising adjuncts to oxaliplatin: state-of-the-art. Pharmacological Research, 2019, 141, 343-356.	7.1	29
114	Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome. Clinical Endocrinology, 2019, 90, 162-169.	2.4	13
115	Narrative review of the effects of antidiabetic drugs on albuminuria. Journal of Cellular Physiology, 2019, 234, 5786-5797.	4.1	16
116	Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2019, 21, 569-574.	4.4	13
117	Metabolic and proteomic signatures of hypoglycaemia in type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 909-919.	4.4	20
118	Effects of acute insulinâ€induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 533-540.	4.4	27
119	Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Food Science and Nutrition, 2019, 59, 1178-1187.	10.3	52
120	Efficacy of artichoke leaf extract in nonâ€alcoholic fatty liver disease: A pilot doubleâ€blind randomized controlled trial. Phytotherapy Research, 2018, 32, 1382-1387.	5.8	43
121	Prediabetes and diabetes in a cohort of Qatari women screened for polycystic ovary syndrome. Scientific Reports, 2018, 8, 3619.	3.3	17
122	Salivary and serum androgens with anti-MÃ $^{1}/_{4}$ llerian hormone measurement for the diagnosis of polycystic ovary syndrome. Scientific Reports, 2018, 8, 3795.	3.3	10
123	Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 691-697.	2.6	86
124	The versatile role of curcumin in cancer prevention and treatment: A focus on PI3K/AKT pathway. Journal of Cellular Physiology, 2018, 233, 6530-6537.	4.1	79
125	Curcumin in heart failure: A choice for complementary therapy?. Pharmacological Research, 2018, 131, 112-119.	7.1	40
126	Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition, 2018, 58, 2549-2556.	10.3	60

#	Article	IF	Citations
127	Dickkopf homolog 3 (<i>DKK3</i>): A candidate for detection and treatment of cancers?. Journal of Cellular Physiology, 2018, 233, 4595-4605.	4.1	23
128	Antiâ€Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clinical Endocrinology, 2018, 88, 258-262.	2.4	28
129	Hyperprolactinaemia in male infertility: Clinical case scenarios. Arab Journal of Urology Arab Association of Urology, 2018, 16, 44-52.	1.5	50
130	Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 2018, 8, e021508.	1.9	14
131	Role of the NLRP3 inflammasome in cancer. Molecular Cancer, 2018, 17, 158.	19.2	310
132	Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Scientific Reports, 2018, 8, 17887.	3.3	48
133	Dynamic Change in Insulin Resistance Induced by Free Fatty Acids Is Unchanged Though Insulin Sensitivity Improves Following Endurance Exercise in PCOS. Frontiers in Endocrinology, 2018, 9, 592.	3.5	11
134	The effect of statin therapy on endoplasmic reticulum stress. Pharmacological Research, 2018, 137, 150-158.	7.1	35
135	Effects of curcumin on hypoxia-inducible factor as a new therapeutic target. Pharmacological Research, 2018, 137, 159-169.	7.1	38
136	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 2018, 20, 2210-2219.	4.4	87
137	Platelet function following induced hypoglycaemia in type 2 diabetes. Diabetes and Metabolism, 2018, 44, 431-436.	2.9	20
138	Monocyteâ€toâ€HDLâ€cholesterol ratio as a prognostic marker in cardiovascular diseases. Journal of Cellular Physiology, 2018, 233, 9237-9246.	4.1	169
139	Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters. International Journal of Hygiene and Environmental Health, 2018, 221, 1068-1075.	4.3	52
140	Assessment of Urinary Deoxynivalenol Biomarkers in UK Children and Adolescents. Toxins, 2018, 10, 50.	3.4	37
141	Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacological Research, 2018, 135, 230-238.	7.1	100
142	Occurrence of deoxynivalenol in an elderly cohort in the UK: a biomonitoring approach. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2018, 35, 2032-2044.	2.3	10
143	Improved physiology and metabolic flux after Roux-en-Y gastric bypass is associated with temporal changes in the circulating microRNAome: a longitudinal study in humans. BMC Obesity, 2018, 5, 20.	3.1	23
144	Changes in Blood microRNA Expression and Early Metabolic Responsiveness 21 Days Following Bariatric Surgery. Frontiers in Endocrinology, 2018, 9, 773.	3.5	31

#	Article	IF	CITATIONS
145	Effect of Soy in Men With Type 2 Diabetes Mellitus and Subclinical Hypogonadism – A Randomized Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2875.	3.6	35
146	Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials. Journal of Diabetes and Its Complications, 2017, 31, 1458-1464.	2.3	19
147	Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. BMC Endocrine Disorders, 2017, 17, 26.	2.2	6
148	Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency. Journal of International Medical Research, 2017, 45, 1708-1719.	1.0	12
149	Curcuminoids Lower Plasma Leptin Concentrations: A Metaâ€analysis. Phytotherapy Research, 2017, 31, 1836-1841.	5.8	22
150	Androstenedione and testosterone levels correlate with in vitro fertilization rates in insulin-resistant women. BMJ Open Diabetes Research and Care, 2017, 5, e000387.	2.8	6
151	ORAI channels are critical for receptor-mediated endocytosis of albumin. Nature Communications, 2017, 8, 1920.	12.8	39
152	Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism – a randomised controlled study. Scientific Reports, 2017, 7, 15366.	3.3	10
153	Salivary testosterone measurement in women with and without polycystic ovary syndrome. Scientific Reports, 2017, 7, 3589.	3.3	10
154	Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial. Journal of Bone and Mineral Research, 2017, 32, 157-164.	2.8	45
155	Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome. Clinical Endocrinology, 2017, 86, 384-387.	2.4	16
156	Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-Blinded Crossover Study. Journal of the Endocrine Society, 2017, 1, 423-430.	0.2	10
157	Deoxynivalenol Biomarkers in the Urine of UK Vegetarians. Toxins, 2017, 9, 196.	3.4	16
158	Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC Endocrine Disorders, 2017, 17, 41.	2.2	6
159	The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population. PLoS ONE, 2017, 12, e0181467.	2.5	31
160	Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care, 2016, 39, 222-230.	8.6	158
161	A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 231-241.	8.6	149
162	Determination of Deoxynivalenol in the Urine of Pregnant Women in the UK. Toxins, 2016, 8, 306.	3 . 4	18

#	Article	IF	Citations
163	Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. Clinical Endocrinology, 2016, 85, 671-673.	2.4	2
164	The dietary flavonol quercetin ameliorates angiotensin Ilâ€induced redox signaling imbalance in a human umbilical vein endothelial cell model of endothelial dysfunction via ablation of p47 ^{phox} expression. Molecular Nutrition and Food Research, 2016, 60, 787-797.	3.3	18
165	Expression and function of transient receptor potential channels in the female bovine reproductive tract. Theriogenology, 2016, 86, 551-561.	2.1	7
166	Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis. Scientific Reports, 2015, 5, 16890.	3.3	61
167	Understanding the Obesity Paradox in Type 2 Diabetes Mellitus. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	1
168	High glucose enhances store-operated calcium entry by upregulating ORAI/STIM via calcineurin-NFAT signalling. Journal of Molecular Medicine, 2015, 93, 511-521.	3.9	45
169	The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocrine Disorders, 2015, 15, 14.	2.2	47
170	The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis. Annals of Internal Medicine, 2015, 162, 610-618.	3.9	147
171	Diabetes and Chocolate: Friend or Foe?. Journal of Agricultural and Food Chemistry, 2015, 63, 9910-9918.	5.2	9
172	LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation. Annals of Clinical Biochemistry, 2015, 52, 180-182.	1.6	7
173	Aspartame Sensitivity? A Double Blind Randomised Crossover Study. PLoS ONE, 2015, 10, e0116212.	2.5	11
174	Patient safety and minimizing risk with insulin administration & mp;ndash; role of insulin degludec. Drug, Healthcare and Patient Safety, 2014, 6, 55.	2.5	21
175	Hollow Pollen Shells to Enhance Drug Delivery. Pharmaceutics, 2014, 6, 80-96.	4.5	91
176	How to measure mood in nutrition research. Nutrition Research Reviews, 2014, 27, 284-294.	4.1	7
177	Weight loss in a UK commercial all meal provision study: a randomised controlled trial. Journal of Human Nutrition and Dietetics, 2014, 27, 377-383.	2.5	4
178	A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clinical Endocrinology, 2014, 80, 843-849.	2.4	19
179	Postprandial effects of longâ€term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome. Diabetes, Obesity and Metabolism, 2014, 16, 545-552.	4.4	10
180	Glucagonâ€ike peptideâ€1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clinical Endocrinology, 2014, 81, 523-528.	2.4	64

#	Article	IF	CITATIONS
181	Weight maintenance over 12Âmonths after weight loss resulting from participation in a 12â€week randomised controlled trial comparing all meal provision to selfâ€directed diet in overweight adults. Journal of Human Nutrition and Dietetics, 2014, 27, 384-390.	2.5	6
182	Acute Hypertriglyceridemia Induces Platelet Hyperactivity That is Not Attenuated by Insulin in Polycystic Ovary Syndrome. Journal of the American Heart Association, 2014, 3, e000706.	3.7	24
183	Insulin Resistance and Cardiovascular Risk Marker Evaluation in Morbid Obesity 12 Months After Bariatric Surgery Compared to Weight-Matched Controls. Obesity Surgery, 2014, 24, 349-358.	2.1	8
184	How does iron interact with sporopollenin exine capsules? An X-ray absorption study including microfocus XANES and XRF imaging. Journal of Materials Chemistry B, 2014, 2, 945-959.	5.8	19
185	Using haemoglobin A1c to diagnose type 2 diabetes or to identify people at high risk of diabetes. BMJ, The, 2014, 348, g2867-g2867.	6.0	15
186	Assessment of Hyperparathyroidism. , 2014, , 235-243.		1
187	Medical Management of Stable Coronary Atherosclerosis. Current Atherosclerosis Reports, 2013, 15, 313.	4.8	6
188	The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily. Diabetes Care, 2013, 36, 858-864.	8.6	214
189	Protein free microcapsules obtained from plant spores as a model for drug delivery: ibuprofen encapsulation, release and taste masking. Journal of Materials Chemistry B, 2013, 1, 707-713.	5.8	85
190	Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clinical Endocrinology, 2013, 79, 252-258.	2.4	28
191	Cardiovascular disease in polycystic ovary syndrome*. Clinical Endocrinology, 2013, 78, 823-824.	2.4	8
192	The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes, Obesity and Metabolism, 2013, 15, 767-769.	4.4	20
193	Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment. Diabetic Medicine, 2013, 30, 1250-1254.	2.3	11
194	Biological variation of cardiovascular risk factors in patients with diabetes. Diabetic Medicine, 2013, 30, 1172-1180.	2.3	12
195	Somatostatin receptor expression in thyroid disease. International Journal of Experimental Pathology, 2013, 94, 226-229.	1.3	33
196	Highâ€polyphenol chocolate reduces endothelial dysfunction and oxidative stress during acute transient hyperglycaemia in TypeÂ2 diabetes: a pilot randomized controlled trial. Diabetic Medicine, 2013, 30, 478-483.	2.3	48
197	Implications of new European Union driving regulations on patients with Type 1 diabetes who participated in the Diabetes Control and Complications Trial. Diabetic Medicine, 2013, 30, 616-619.	2.3	15
198	TRPC Channels and Their Splice Variants are Essential for Promoting Human Ovarian Cancer Cell Proliferation and Tumorigenesis. Current Cancer Drug Targets, 2013, 13, 103-116.	1.6	65

#	Article	IF	Citations
199	TRPC channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis. Current Cancer Drug Targets, 2013, 13, 103-16.	1.6	32
200	Insulin degludec – a new-generation basal insulin. Expert Opinion on Biological Therapy, 2012, 12, 539-542.	3.1	3
201	Activation of TRPC Cationic Channels by Mercurial Compounds Confers the Cytotoxicity of Mercury Exposure. Toxicological Sciences, 2012, 125, 56-68.	3.1	33
202	MECHANISMS IN ENDOCRINOLOGY: Recent advances in cardiovascular aspects of polycystic ovary syndrome. European Journal of Endocrinology, 2012, 166, 575-583.	3.7	51
203	Efficacy and safety of ultra-long-acting insulin degludec. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 55-59.	3.2	8
204	Atorvastatin Reduces Malondialdehyde Concentrations in Patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3951-3955.	3.6	30
205	Does severe hypoglycaemia influence microvascular complications in Type 1 diabetes? An analysis of the Diabetes Control and Complications Trial database. Diabetic Medicine, 2012, 29, 1195-1198.	2.3	19
206	Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry, 2012, 49, 80-85.	1.6	29
207	Sequestration of edible oil from emulsions using new single and double layered microcapsules from plant spores. Journal of Materials Chemistry, 2012, 22, 9767.	6.7	41
208	Does equol production determine soy endocrine effects?. European Journal of Nutrition, 2012, 51, 389-398.	3.9	50
209	The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clinical Endocrinology, 2012, 76, 196-200.	2.4	33
210	Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels. Biochemical Pharmacology, 2012, 83, 923-931.	4.4	34
211	Shortâ€term glucose variability in healthy volunteers is not associated with raised oxidative stress markers. Diabetes, Obesity and Metabolism, 2012, 14, 1047-1049.	4.4	9
212	Use of Carotid Intima-Media Thickness Regression to Guide Therapy and Management of Cardiac Risks. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 50-56.	0.9	5
213	The Biological Variation of N-Terminal Pro-Brain Natriuretic Peptide in Postmenopausal Women with Type 2 Diabetes: A Case Control Study. PLoS ONE, 2012, 7, e47191.	2.5	3
214	Storeâ€operated calcium channel Orai and STIM regulated by high glucose. FASEB Journal, 2012, 26, 884.12.	0.5	0
215	Viability of plant spore exine capsules for microencapsulation. Journal of Materials Chemistry, 2011, 21, 975-981.	6.7	79
216	The effect of extensive flooding in Hull on the glycaemic control of patients with diabetes. Diabetic Medicine, 2011, 28, 519-524.	2.3	32

#	Article	IF	Citations
217	Pharmacological Treatment of Obesity in Patients with Polycystic Ovary Syndrome. Journal of Obesity, 2011, 2011, 1-6.	2.7	8
218	Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant. Diabetic Medicine, 2011, 28, 124-125.	2.3	0
219	Pituitary hypophysitis and gulf war syndrome: a case series and hypothesis. Clinical Endocrinology, 2011, 75, 272-274.	2.4	3
220	Endocrine disruptor & Description and Genetics, 2011, 28, 1223-1228.	2.5	36
221	UV and visible light screening by individual sporopollenin exines derived from Lycopodium clavatum (club moss) and Ambrosia trifida (giant ragweed). Journal of Photochemistry and Photobiology B: Biology, 2011, 102, 209-217.	3.8	58
222	The Effect of Soy Phytoestrogen Supplementation on Thyroid Status and Cardiovascular Risk Markers in Patients with Subclinical Hypothyroidism: A Randomized, Double-Blind, Crossover Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1442-1449.	3.6	81
223	Investigating hyponatraemia. BMJ: British Medical Journal, 2011, 342, d1118-d1118.	2.3	13
224	Postural hypotension. BMJ: British Medical Journal, 2011, 342, d3128-d3128.	2.3	6
225	Defining failure after parathyroidectomy for primary hyperparathyroidism: case series. Journal of Laryngology and Otology, 2011, 125, 394-398.	0.8	2
226	Insulin Resistance Variability in Women with Anovulatory and Ovulatory Polycystic Ovary Syndrome, and Normal Controls. Hormone and Metabolic Research, 2011, 43, 141-145.	1.5	10
227	Endothelial Function and Stress Response After Simulated Dives to 18 msw Breathing Air or Oxygen. Aviation, Space, and Environmental Medicine, 2010, 81, 41-45.	0.5	47
228	Enhanced Bioavailability of Eicosapentaenoic Acid from Fish Oil After Encapsulation Within Plant Spore Exines as Microcapsules. Lipids, 2010, 45, 645-649.	1.7	64
229	Electrochemistry and charge transport in sporopollenin particle arrays. Electrochemistry Communications, 2010, 12, 1428-1431.	4.7	10
230	Effect of rimonabant and metformin on glucoseâ€dependent insulinotropic polypeptide and glucagonâ€ike peptideâ€i in obese women with polycystic ovary syndrome. Clinical Endocrinology, 2010, 72, 423-425.	2.4	4
231	Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2010, 72, 566-568.	2.4	30
232	Low density lipoproteinâ€cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?. Diabetes, Obesity and Metabolism, 2010, 12, 540-544.	4.4	7
233	Impaired fasting glucose and impaired glucose tolerance: followâ€up rates over 2â€∫years within a primary care setting. Diabetic Medicine, 2010, 27, 123-123.	2.3	0
234	New recommendations in diagnosis of diabetes mellitus from the Department of Health: comparing the old and new. Diabetic Medicine, 2010, 27, 244-245.	2.3	2

#	Article	IF	CITATIONS
235	For debate.Glucose variability and diabetes complication risk: we need to know the answer. Diabetic Medicine, 2010, 27, 868-871.	2.3	42
236	Highâ€cocoa polyphenolâ€rich chocolate improves HDL cholesterol in Typeâ€f2 diabetes patients. Diabetic Medicine, 2010, 27, 1318-1321.	2.3	124
237	Antioxidant-rich spice added to hamburger meat during cooking results in reduced meat, plasma, and urine malondialdehyde concentrations. American Journal of Clinical Nutrition, 2010, 92, 996-997.	4.7	23
238	The Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease. Diabetes Care, 2010, 33, 2310-2313.	8.6	93
239	The Role of Blood Pressure Variability in the Development of Nephropathy in Type 1 Diabetes. Diabetes Care, 2010, 33, 2442-2447.	8.6	74
240	Management of carcinoma showing thymus-like element. Journal of Laryngology and Otology, 2010, 124, 1242-1244.	0.8	1
241	Evidence for statin therapy in polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 2010, 1, 15-22.	3.2	15
242	Disparate Effects of Atorvastatin Compared With Simvastatin on C-Reactive Protein Concentrations in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, 1948-1950.	8.6	12
243	Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity. Mediators of Inflammation, 2010, 2010, 1-5.	3.0	67
244	Atorvastatin Increases 25-Hydroxy Vitamin D Concentrations in Patients with Polycystic Ovary Syndrome. Clinical Chemistry, 2010, 56, 1696-1700.	3.2	48
245	Insulin resistance and free androgen index correlate with the outcome of controlled ovarian hyperstimulation in non-PCOS women undergoing IVF. Human Reproduction, 2010, 25, 504-509.	0.9	39
246	Subclinical Hypothyroidism Is Associated With Reduced All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, e37-e37.	8.6	24
247	Obesity and gestational diabetes. Seminars in Fetal and Neonatal Medicine, 2010, 15, 89-93.	2.3	34
248	High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome. Nutrition Journal, 2010, 9, 55.	3.4	60
249	Sporopollenin exines: A novel natural taste masking material. LWT - Food Science and Technology, 2010, 43, 73-76.	5.2	57
250	Access to a primary aminosporopollenin solid support from plant spores. Green Chemistry, 2010, 12, 234-240.	9.0	30
251	A persistent headache. BMJ: British Medical Journal, 2010, 340, c2966-c2966.	2.3	0
252	Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis. Climacteric, 2009, 12, 427-430.	2.4	5

#	Article	IF	Citations
253	The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 103-108.	3.6	129
254	Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes. Diabetes Care, 2009, 32, 1901-1903.	8.6	124
255	Initial investigation of amenorrhoea. BMJ: British Medical Journal, 2009, 339, b2184-b2184.	2.3	2
256	Hypoglycemia and Clinical Outcomes in Patients With Diabetes Hospitalized in the General Ward: Response to Turchin et al Diabetes Care, 2009, 32, e151-e151.	8.6	6
257	Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart, 2009, 95, 917-923.	2.9	48
258	The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes. Annals of Clinical Biochemistry, 2009, 46, 218-221.	1.6	9
259	Multiple mechanisms of soy isoflavones against oxidative stress-induced endothelium injury. Free Radical Biology and Medicine, 2009, 47, 167-175.	2.9	54
260	Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia, 2009, 52, 2229-2232.	6.3	65
261	Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clinical Endocrinology, 2009, 70, 233-237.	2.4	66
262	Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2009, 70, 124-128.	2.4	7
263	The Diabetes Control and Complications Trial: the gift that keeps giving. Nature Reviews Endocrinology, 2009, 5, 537-545.	9.6	46
264	MRI contrast agent delivery using spore capsules: controlled release in blood plasma. Chemical Communications, 2009, , 6442.	4.1	53
265	Investigating hirsutism. BMJ: British Medical Journal, 2009, 338, b912-b912.	2.3	8
266	Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia, 2008, 51, 365-371.	6.3	73
267	The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology. European Archives of Oto-Rhino-Laryngology, 2008, 265, 63-67.	1.6	27
268	Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2. Journal of Thrombosis and Haemostasis, 2008, 6, 692-700.	3.8	34
269	Variability of lipids in patients with TypeÂ2 diabetes taking statin treatment: implications for target setting. Diabetic Medicine, 2008, 25, 909-915.	2.3	12
270	Home administration of lanreotide Autogel $\sup \hat{A}^{\otimes}$ (sup> by patients with acromegaly, or their partners, is safe and effective. Clinical Endocrinology, 2008, 68, 343-349.	2.4	55

#	Article	IF	Citations
271	Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clinical Endocrinology, 2008, 68, 390-394.	2.4	30
272	Alterations in thyroid status do not affect plasma peptide YY (PYY) and ghrelin concentrations. Clinical Endocrinology, 2008, 68, 836-838.	2.4	6
273	A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized openâ€label parallel study. Clinical Endocrinology, 2008, 69, 931-935.	2.4	27
274	Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review. Clinical Endocrinology, 2008, 69, 831-844.	2.4	20
275	A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes. Diabetes Care, 2008, 31, 2198-2202.	8.6	377
276	Expression of Somatostatin and Somatostatin Receptor Subtypes $1\hat{a}\in$ 5 in Human Normal and Diseased Kidney. Journal of Histochemistry and Cytochemistry, 2008, 56, 733-743.	2.5	61
277	Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology, 2008, 159, R11-R14.	3.7	102
278	Variability in the Relationship between Mean Plasma Glucose and HbA1c: Implications for the Assessment of Glycemic Control. Clinical Chemistry, 2007, 53, 897-901.	3.2	85
279	Thiazolidinediones, deadly sins, surrogates, and elephants. Lancet, The, 2007, 370, 1103-1104.	13.7	30
280	Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes: "Double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care, 2007, 30, 707-712.	8.6	347
281	The relationship between mean glucose and HbA1cin premenopausal women compared with males in the Diabetes Control and Complications Trial. Diabetic Medicine, 2007, 25, 071119221323007-???.	2.3	6
282	Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes. Diabetes Care, 2007, 30, 1871-1873.	8.6	59
283	Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia, 2007, 50, 2553-2561.	6.3	193
284	Mechanism of action of octreotide in acromegalic tumours inÂvivo using dynamic contrast-enhanced magnetic resonance imaging. Pituitary, 2007, 10, 233-236.	2.9	7
285	Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Pituitary, 2007, 10, 261-266.	2.9	12
286	How we do it: Surgery should be considered equally with I131 and thionamide treatment as first-line therapy for thyrotoxicosis. Clinical Otolaryngology, 2006, 31, 160-162.	0.0	3
287	Intra-operative parathyroid hormone monitoring in secondary hyperparathyroidism: is it useful?. Clinical Otolaryngology, 2006, 31, 198-203.	0.0	19
288	Dehydroepiandrosterone sulphate interferes with the Abbott Architect direct immunoassay for testosterone. Annals of Clinical Biochemistry, 2006, 43, 196-199.	1.6	33

#	Article	IF	Citations
289	The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Annals of Clinical Biochemistry, 2006, 43, 217-219.	1.6	47
290	The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes. Diabetes Care, 2006, 29, 1486-1490.	8.6	317
291	The effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide concentrations. Annals of Clinical Biochemistry, 2006, 43, 184-188.	1.6	5
292	Thyroidectomy does not cause globus pattern symptoms. Journal of Laryngology and Otology, 2005, 119, 973-975.	0.8	28
293	Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change. Diabetic Medicine, 2005, 22, 344-345.	2.3	0
294	Does thyroid subspecialization alter practice and outcome? A completed 4-year audit loop. Clinical Otolaryngology, 2005, 30, 48-51.	1.2	12
295	Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. British Journal of Cancer, 2005, 92, 1493-1498.	6.4	93
296	Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 729-733.	3.6	128
297	The Biological Variation of C-Reactive Protein in Polycystic Ovarian Syndrome. Clinical Chemistry, 2005, 51, 1905a-1907.	3.2	15
298	The Biological Variation of Sex Hormone-Binding Globulin in Type 2 Diabetes: Implications for sex hormone-binding globulin as a surrogate marker of insulin resistance. Diabetes Care, 2004, 27, 278-280.	8.6	31
299	The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas. Journal of Clinical Pathology, 2004, 57, 168-171.	2.0	10
300	Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84. Diabetes, Obesity and Metabolism, 2004, 6, 344-352.	4.4	18
301	Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clinical Endocrinology, 2004, 61, 431-436.	2.4	33
302	Hypopituitarism presenting as a mixed hyperlipidaemia. Annals of Clinical Biochemistry, 2004, 41, 344-345.	1.6	1
303	Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer. Journal of Laryngology and Otology, 2004, 118, 653-654.	0.8	2
304	The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. Clinical Otolaryngology, 2003, 28, 314-319.	0.0	14
305	Paradoxical Changes in Cystatin C and Serum Creatinine in Patients with Hypo- and Hyperthyroidism. Clinical Chemistry, 2003, 49, 680-681.	3.2	88
306	The Biological Variation of Testosterone and Sex Hormone-Binding Globulin (SHBG) in Polycystic Ovarian Syndrome: Implications for SHBG as a Surrogate Marker of Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1528-1533.	3.6	117

#	Article	IF	Citations
307	Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor Size. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4554-4563.	3.6	267
308	The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1560-1562.	3.6	28
309	Biological Variation of Homeostasis Model Assessment-Derived Insulin Resistance in Type 2 Diabetes. Diabetes Care, 2002, 25, 2022-2025.	8.6	45
310	Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. Journal of Endocrinology, 2002, 174, 7-16.	2.6	63
311	Beneficial Effects of Soy Phytoestrogen Intake in Postmenopausal Women With Type 2 Diabetes. Diabetes Care, 2002, 25, 1709-1714.	8.6	308
312	Hyperparthyroidism in elderly osteopenic women. Maturitas, 2002, 43, 245-249.	2.4	2
313	Somatostatin receptorÂ2 expression in the human endometrium through the menstrual cycle. Clinical Endocrinology, 2002, 56, 609-614.	2.4	14
314	Somatostatins and their role in thyroid cancer. Clinical Otolaryngology, 2002, 27, 120-123.	0.0	2
315	Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. British Journal of Cancer, 2002, 87, 86-90.	6.4	20
316	Dexamethasone blocks antioestrogen- and oxidant-induced death of pituitary tumour cells. Journal of Endocrinology, 2001, 169, 249-261.	2.6	8
317	Autoimmune Hypothyroidism Coexisting with a Pituitary Adenoma Secreting Thyroid-Stimulating Hormone, Prolactin and α-Subunit. Annals of Clinical Biochemistry, 2001, 38, 566-571.	1.6	17
318	Autoimmune hypothyroidism coexisting with a pituitary adenoma secreting thyroid-stimulating hormone, prolactin and \hat{l}_{\pm} -subunit. Annals of Clinical Biochemistry, 2001, 38, 566-571.	1.6	10
319	CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clinical Endocrinology, 2000, 52, 43-49.	2.4	89
320	Identification of Wild-Type and Exon 5 Deletion Variants of Estrogen Receptor \hat{l}^2 in Normal Human Mammary Gland1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1601-1605.	3.6	49
321	Neuroleptic malignant syndrome after venlafaxine. Lancet, The, 2000, 355, 289-290.	13.7	36
322	Response of estrogen receptor containing tumour cells to pure antiestrogens and the calmodulin inhibitor, calmidzolium chloride. Journal of Steroid Biochemistry and Molecular Biology, 2000, 73, 29-38.	2.5	14
323	Functional inactivation of the oestrogen receptor by the antioestrogen, ZM 182780, sensitises tumour cells to reactive oxygen species. Journal of Endocrinology, 1999, 161, 199-210.	2.6	12
324	Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. British Journal of Cancer, 1999, 80, 898-903.	6.4	53

#	Article	IF	CITATIONS
325	In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6. British Journal of Cancer, 1999, 81, 690-695.	6.4	28
326	Activity and gene expression of $17\hat{l}^2$ -hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. Journal of Steroid Biochemistry and Molecular Biology, 1998, 67, 267-274.	2.5	57
327	Identification of proliferating human anterior pituitary adenoma cells in vitro. Neurological Research, 1997, 19, 420-425.	1.3	3
328	Anin vitro model of diabetes. In Vitro Cellular and Developmental Biology - Animal, 1996, 32, 379-381.	1.5	2
329	Hypotonic lysis of red blood cell contamination from human anterior pituitary adenoma cell preparations. In Vitro Cellular and Developmental Biology - Animal, 1995, 31, 657-658.	1.5	5
330	Multiple Cerebral Haematomata and Peripheral Nerve Palsies Associated with a Case of Juvenile Diabetic Ketoacidosis. Diabetic Medicine, 1995, 12, 267-270.	2.3	20
331	Isolated adrenocorticotropin deficiency presenting as primary infertility. Journal of Endocrinological Investigation, 1995, 18, 456-459.	3.3	6
332	Effects of insulinâ€like growth factorâ€l on growth hormone and prolactin secretion and cell proliferation of human somatotrophinomas and prolactinomas <i>in vitro</i> . Clinical Endocrinology, 1994, 41, 503-509.	2.4	20
333	d-Valine selective medium does not inhibit human fibroblast growth in vitro. In Vitro Cellular and Developmental Biology - Animal, 1993, 29, 912-913.	1.5	6
334	A superior method for single cell dispersal of rat and tumorous human anterior pituitary tissue. In Vitro Cellular & Developmental Biology, 1993, 29, 1-3.	1.0	18
335	Basic fibroblastic growth factor stimulates prolactin secretion from human anterior pituitary adenomas without affecting adenoma cell proliferation Journal of Clinical Endocrinology and Metabolism, 1993, 77, 831-837.	3.6	26
336	Differential effects of insulin-like growth factor 1 on the hormonal product and proliferation of glycoprotein-secreting human pituitary adenomas Journal of Clinical Endocrinology and Metabolism, 1993, 77, 1059-1066.	3.6	24
337	Increased Insulin Requirement in a Patient with Type 1 Diabetes on Rifampicin. Diabetic Medicine, 1993, 10, 392-392.	2.3	16
338	Carbamazepine-induced lichenoid eruption. Clinical and Experimental Dermatology, 1990, 15, 382-383.	1.3	30
339	Clinical and laboratory studies in patients with leprosy and enthesitis Annals of the Rheumatic Diseases, 1990, 49, 715-717.	0.9	11
340	Clinical and laboratory studies of inflammatory polyarthritis in patients with leprosy in Papua New Guinea Annals of the Rheumatic Diseases, 1987, 46, 688-690.	0.9	33
341	ICHTHYOSIS RESOLVING AFTER RENAL TRANSPLANTATION. Lancet, The, 1987, 329, 743-744.	13.7	3
342	Lactation by a Commissioning Mother in Surrogacy. , 0, , 412-414.		0